Skip to main content

Cytosar Disease Interactions

There are 4 disease interactions with Cytosar (cytarabine).

Major

Antineoplastics (applies to Cytosar) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
  2. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
  3. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
  4. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
  5. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
  6. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
  8. "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
  9. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
  10. "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
  11. "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
  12. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
  14. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
  15. "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
  16. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
  17. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
  19. "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
  21. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  22. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
  27. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  28. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  29. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 29 references
Major

Cytarabine (applies to Cytosar) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever, Bleeding

Cytarabine is a potent bone marrow suppressant. Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood. Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.

References

  1. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
Moderate

Cytarabine (applies to Cytosar) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Cytarabine is extensively metabolized by the liver. Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy. Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function. Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.

References

  1. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
Moderate

Cytarabine (applies to Cytosar) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Cytarabine is primarily eliminated by the kidney. Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy. Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function. Periodic checks of kidney function should be performed in patients receiving Cytarabine.

References

  1. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):

Cytosar drug interactions

There are 270 drug interactions with Cytosar (cytarabine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer